Back

A CRISPR-Based Humanized Model Reveals Cooperative Role of STAG2 Loss in Familial GATA2-Deficient MDS Progression

Freed, G.; Quijada-Alamo, M.; Lee, L.; Poddar, N.; Autar, S.; Carcamo, S.; Fiore, P.; Wang, K.; Martinez, I. G.; Zhang, M.; Saniei, S.; Chao, C.; Mekerishvili, L.; Diaz, Z.; Ma, S.; Hasson, D.; Wagenblast, E.

2026-02-02 cancer biology
10.64898/2026.01.30.702879 bioRxiv
Show abstract

Myelodysplastic syndrome (MDS) is a heterogeneous myeloid malignancy driven by hematopoietic stem cell dysfunction, leading to ineffective hematopoiesis and cytopenias. Familial GATA2 deficiency is the most common cause of Myelodysplastic syndrome in adolescents, with progression often accelerated by co-occurring mutations, notably STAG2 loss-of-function. Using CRISPR/Cas9-mediated genome engineering in primary human fetal liver-derived hematopoietic stem cells and xenotransplantation in mice, we modeled GATA2-deficient Myelodysplastic syndrome with acquired STAG2 loss to investigate disease initiation and progression. While GATA2 deficiency alone had minimal short-term impact in our model, combined GATA2 and STAG2 loss increased hematopoietic stem cell maintenance and self-renewal, induced a myeloid-lineage bias, and expanded primitive progenitors. Single-cell transcriptional profiling revealed upregulation of stemness genes and inflammatory pathways. This humanized model faithfully recapitulates high-risk GATA2-deficient Myelodysplastic syndrome, providing mechanistic insight into how cooperative mutations drive stem cell expansion, inflammatory signaling, and myeloid skewing. Visual Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=119 SRC="FIGDIR/small/702879v1_ufig1.gif" ALT="Figure 1"> View larger version (20K): org.highwire.dtl.DTLVardef@1972beforg.highwire.dtl.DTLVardef@1c57886org.highwire.dtl.DTLVardef@16bd582org.highwire.dtl.DTLVardef@8e728a_HPS_FORMAT_FIGEXP M_FIG C_FIG Key PointsO_LIHumanized model of familial GATA2-deficiency requires the loss of STAG2 for progression to an MDS disease phenotype C_LIO_LIGATA2-ko+STAG2-ko increase HSC self-renewal, induce a myeloid-lineage bias, and trigger an inflammatory transcriptional program C_LI

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
Blood
67 papers in training set
Top 0.1%
22.2%
2
Blood Advances
54 papers in training set
Top 0.2%
6.7%
3
Cancer Discovery
61 papers in training set
Top 0.2%
6.3%
4
Leukemia
39 papers in training set
Top 0.2%
6.3%
5
Journal of Clinical Investigation
164 papers in training set
Top 0.8%
3.9%
6
Nature
575 papers in training set
Top 6%
3.9%
7
Nature Genetics
240 papers in training set
Top 2%
3.5%
50% of probability mass above
8
Haematologica
24 papers in training set
Top 0.2%
3.5%
9
Nature Communications
4913 papers in training set
Top 40%
3.5%
10
Cell Reports
1338 papers in training set
Top 15%
3.5%
11
Cell Stem Cell
57 papers in training set
Top 0.5%
3.5%
12
Science Translational Medicine
111 papers in training set
Top 1%
3.0%
13
eLife
5422 papers in training set
Top 36%
2.0%
14
Experimental Hematology
11 papers in training set
Top 0.1%
2.0%
15
Genes & Development
90 papers in training set
Top 0.4%
1.8%
16
Science
429 papers in training set
Top 14%
1.7%
17
JCI Insight
241 papers in training set
Top 4%
1.6%
18
Nature Cancer
35 papers in training set
Top 0.8%
1.6%
19
Cell Reports Medicine
140 papers in training set
Top 4%
1.5%
20
Journal of Experimental Medicine
106 papers in training set
Top 2%
1.5%
21
EMBO Molecular Medicine
85 papers in training set
Top 3%
1.2%
22
Nature Medicine
117 papers in training set
Top 4%
0.9%
23
Genome Medicine
154 papers in training set
Top 7%
0.9%
24
Clinical Cancer Research
58 papers in training set
Top 2%
0.9%
25
Cell Genomics
162 papers in training set
Top 7%
0.7%
26
The American Journal of Human Genetics
206 papers in training set
Top 4%
0.7%
27
Stem Cell Reports
118 papers in training set
Top 1%
0.6%